|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,001.10 INR | +0.56% |
|
+2.99% | +16.36% |
| 08:34am | Sun Pharma Gets Brazil Approval for Semaglutide Injection | MT |
| 07-21 | South Africa regulator reviews 12 generic semaglutide applications | RE |
| Market Cap | 4,801B 50.29B 43.68B 40.57B 37.41B 70.47B 71.75B 480B 188B 2,385B 189B 185B 8,019B | P/E 2027 * |
36.7x | P/E 2028 * | 31.1x |
|---|---|---|---|---|---|
| Enterprise Value | 4,538B 47.53B 41.29B 38.34B 35.36B 66.6B 67.81B 454B 178B 2,254B 178B 175B 7,579B | EV / Sales 2027 * |
6.94x | EV / Sales 2028 * | 6.13x |
| Free-Float |
44.39% | Yield 2027 * |
0.79% | Yield 2028 * | 0.88% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.56% | ||
| 1 week | +2.99% | ||
| Current month | +7.44% | ||
| 1 month | +6.74% | ||
| 3 months | +12.50% | ||
| 6 months | +25.91% | ||
| Current year | +16.36% |
| 1 week | 1,933 |  | 2,017.3 |
| 1 month | 1,860.2 | | 2,017.3 |
| Current year | 1,583.7 | | 2,017.3 |
| 1 year | 1,548 | | 2,017.3 |
| 3 years | 1,068.35 | | 2,017.3 |
| 5 years | 733.7 | | 2,017.3 |
| 10 years | 312 | | 2,017.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 01/09/2025 | |
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.56% | +2.99% | +16.99% | +75.76% | 49.85B | |
| -1.74% | +3.05% | +56.51% | +109.86% | 36.89B | |
| -0.54% | +3.63% | -6.84% | +24.50% | 12.43B | |
| -0.68% | -0.99% | +12.09% | +74.10% | 11.69B | |
| +2.86% | +0.96% | +31.25% | +132.30% | 9.04B | |
| -1.36% | +2.18% | +48.00% | -5.72% | 7.15B | |
| +0.34% | 0.00% | +12.99% | +33.94% | 6.7B | |
| -3.16% | -0.44% | +1.50% | +174.22% | 6.66B | |
| +0.21% | -3.66% | -34.95% | -1.46% | 5.45B | |
| +1.17% | -0.65% | +21.72% | +112.68% | 4.43B | |
| Average | -0.23% | +1.90% | +15.93% | +73.02% | 15.03B | |
| Weighted average by Cap. | -0.31% | +2.69% | +24.06% | +80.08% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 654B 6.85B 5.95B 5.53B 5.1B 9.6B 9.78B 65.45B 25.62B 325B 25.74B 25.17B 1,093B | 730B 7.64B 6.64B 6.17B 5.69B 10.71B 10.9B 72.99B 28.58B 362B 28.7B 28.07B 1,219B |
| Net income | 132B 1.38B 1.2B 1.12B 1.03B 1.94B 1.97B 13.22B 5.18B 65.64B 5.2B 5.08B 221B | 156B 1.63B 1.42B 1.32B 1.22B 2.29B 2.33B 15.61B 6.11B 77.5B 6.14B 6B 261B |
| Net Debt | -263B -2.76B -2.4B -2.23B -2.05B -3.87B -3.94B -26.35B -10.32B -131B -10.36B -10.14B -440B | -329B -3.44B -2.99B -2.78B -2.56B -4.82B -4.91B -32.88B -12.87B -163B -12.93B -12.65B -549B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/07/26 | ₹2,001.10 | +0.56% | 2,224,264 |
| 29/07/26 | ₹1,989.90 | +0.67% | 2,682,295 |
| 28/07/26 | ₹1,976.70 | +0.15% | 4,579,529 |
| 27/07/26 | ₹1,973.70 | +1.68% | 5,414,380 |
| 24/07/26 | ₹1,941.10 | -0.66% | 1,578,929 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
